Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.
about
Deep Response in Multiple Myeloma: A Critical ReviewNew criteria for response assessment: role of minimal residual disease in multiple myelomaPost-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple MyelomaComment on "Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy"Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma PatientsT-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of ImmunotherapyNovel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases.Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myelomaSerum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myelomaMinimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.Posttransplant maintenance therapy in multiple myeloma: the changing landscape.Controversies in multiple myeloma: to transplant or not?Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.Myeloma Propagating Cells, Drug Resistance and Relapse.Oral ixazomib maintenance therapy in multiple myeloma.Risk Stratification in Multiple Myeloma.Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents.Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma.Multiple myeloma: disease response assessment.Multiple Myeloma Minimal Residual Disease.VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Standardisation of minimal residual disease in multiple myeloma.Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.Maintenance therapy in multiple myeloma.Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.
P2860
Q26771228-A01FE456-D35B-4855-968E-942E46285AA7Q27027512-26530BE7-E5C2-4F4E-9B4C-D2B7AE483805Q34694749-A45B93B7-965F-4FD0-9C18-67256943CB49Q35226933-3CEDFB27-08AC-4C30-8BD8-B7608FC89615Q36115680-4BDBE02E-B71F-461C-A3A1-785AD8DD81FAQ36137449-2FDF85B2-F797-45CB-83BA-0C0707ECA31FQ36205711-0642FA36-B713-4620-B274-2D741A5CAD33Q36436758-061F3D89-FA8D-409A-9815-318FA92537A8Q36502820-383EC69F-109F-4E3E-A970-05A4EAE3BA31Q36562341-5BC43930-2E01-49C9-BEF4-5BBB0EED1F2AQ37313790-16757D10-F83E-497B-9347-0466BACC4A22Q37528072-6E5170F3-BCA7-46BF-9772-923552A9C71AQ37701511-B6B5300B-8A34-4DFE-9454-C18912F54F77Q37737800-4717E4BF-A91E-48C5-B181-46AE58A135D9Q38242006-3A2A1704-B46C-4460-87F2-C5DDCB2A448FQ38249930-EB3D048F-98D3-440B-851B-C966F00CDA9EQ38255333-719098FB-C816-4838-98EB-33C243764882Q38393649-F8F46106-0EC1-4395-AD39-1E817ADDBA23Q38398899-C66FD03C-B806-4B89-8D03-62A5017E44DCQ38429817-C7D835D7-1298-43E9-A25D-FD6174B9AD86Q38543122-975A40C5-47D6-4203-8F6D-B026133C2511Q38572771-DEB6E29B-4CA7-4563-843C-203BA26B343CQ38640514-BD9D9E82-926F-44FE-972E-2C0DE7D72385Q38736249-ADB814B9-55BB-4F01-8F92-454D1139A79CQ38740213-E4EE7975-BE78-4EF3-A387-212326DF8A1EQ38832949-19FBC50F-CE42-469F-8321-6221FABC53AEQ38895092-EC6DAE56-0F7B-493F-9127-F1960C60A7CAQ38970590-63293A56-75C2-42CE-BE68-3F8503FBD804Q39103567-A12CF185-FB68-4303-9D30-8B840287E71EQ39177792-2DA8ED28-6B62-484E-91B9-77E1B2790A4FQ39410899-A230D9AC-72FD-4273-B518-662EA5EC1E33Q39518931-2739302E-A3E7-4F0F-9975-22F8849B6191Q40273400-4FB007A1-27FE-4E0F-8B29-59A9536B1E2CQ40368431-26EF1F12-F779-4635-8125-7B0F163DBBC4Q40389797-75CCBFB7-495A-4795-878E-C065391836A6Q40469944-4735AC79-D076-434E-B2D7-75EE97996ADCQ40562696-0DD0FE39-26B5-4434-852C-99809AD11AB0Q40649641-7507330F-98F6-4C02-B4E0-418924CF677BQ42323127-CDE73771-DCC4-4218-BB6C-1FA241634A8BQ42715379-A2F42EAE-0775-4035-B763-4D4245217919
P2860
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Importance of achieving string ...... lantation in multiple myeloma.
@en
Importance of achieving string ...... lantation in multiple myeloma.
@nl
type
label
Importance of achieving string ...... lantation in multiple myeloma.
@en
Importance of achieving string ...... lantation in multiple myeloma.
@nl
prefLabel
Importance of achieving string ...... lantation in multiple myeloma.
@en
Importance of achieving string ...... lantation in multiple myeloma.
@nl
P2093
P2860
P50
P356
P1476
Importance of achieving string ...... lantation in multiple myeloma.
@en
P2093
Arleigh McCurdy
Francis Buadi
John A Lust
Nelson Leung
Philip R Greipp
Prashant Kapoor
Shaji K Kumar
Thomas E Witzig
P2860
P304
P356
10.1200/JCO.2013.49.0086
P407
P50
P577
2013-11-18T00:00:00Z